Safety, Tolerability, and Pharmacokinetics of NIM-1324 an Oral LANCL2 Agonist in a Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial在一项随机,双盲,安慰剂对照的I期临床试验中NIM-1324口服LANCL2激动剂的安全性,耐受性和药代动力学CTS-CLINICAL AND TRANSLATIONAL SCIENCEIF2.82025-01-100OA
Blockade of IL-18 signaling downregulates homing of effector CD4+T cells to the gut mucosa and provides protection from experimental IBDJOURNAL OF IMMUNOLOGYIF3.42023-05-010OA
Activation of NLRX1 by NX-13 Alleviates Inflammatory Bowel Disease through Immunometabolic Mechanisms in CD4+ T CellsJOURNAL OF IMMUNOLOGYIF3.42019-12-1535OAAI
Exploratory studies with NX-13: oral toxicity and pharmacokinetics in rodents of an orally active, gut-restricted first-in-class therapeutic for IBD that targets NLRX1DRUG AND CHEMICAL TOXICOLOGYIF1.92019-10-2516OAAI
Nutritional regulation of porcine bacterial-induced colitis by conjugated linoleic acidJOURNAL OF NUTRITIONIF3.82002-07-01157OAAI
Dietary conjugated linoleic acid modulates phenotype and effector functions of porcine CD8+ lymphocytesJOURNAL OF NUTRITIONIF3.82001-09-0174OAAI